Introduction to
Somatic Mutation-Profiled FFPE Samples
Buy FFPE Somatic Mutation-Profiled Tumor Samples
FFPE somatic mutation-profiled tumour samples provide preserved cancer tissue accompanied by molecular findings identifying acquired genomic alterations within the tumour. Depending on the testing method, the profile may include single-nucleotide variants, insertions, deletions, copy-number alterations and selected gene fusions. These samples can support oncology research, drug development, assay validation and studies involving targeted therapies. Researchers may select cases carrying specific alterations in genes such as EGFR, KRAS, BRAF, PIK3CA, TP53, BRCA1 or BRCA2.
Before purchasing, it is important to review the sequencing platform, gene-panel content, variant allele frequency, coverage and classification of each reported alteration. Researchers should also determine whether matched normal DNA was tested to distinguish somatic findings from possible germline variants. Pathologist-reviewed H&E slides can confirm diagnosis, tumour percentage, necrosis and tissue sufficiency. Carefully sourced, ethically approved and de-identified somatic mutation-profiled FFPE tumour samples can reduce prescreening requirements and facilitate the development of focused molecular cohorts.
FFPE Somatic Mutation -Profiled Blocks for Cancer Research
FFPE somatic mutation-profiled blocks allow cancer researchers to investigate how acquired genetic alterations influence tumour biology, morphology and potential treatment sensitivity. The tissue can be selected according to cancer indication, histological subtype, mutation status, disease stage or previous treatment. Existing molecular results can be compared with newly generated data from IHC, FISH, PCR, RNA analysis, spatial biology or repeat sequencing. This approach can support studies of oncogenic drivers, resistance mechanisms, tumour heterogeneity and molecular pathways
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Source Clinically Annotated Somatic Mutation-Positive FFPE Samples
Clinically annotated, somatic mutation-positive FFPE samples combine confirmed tumour alterations with pathological and patient-level information. Researchers can request samples carrying particular mutations and further define the cohort according to diagnosis, stage, grade, primary or metastatic status and treatment exposure. Available clinical information may include therapies administered, response, progression and follow-up, subject to consent and data availability.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
FFPE Tumor Blocks With Validated Somatic Mutation Data
FFPE tumour blocks with validated somatic mutation data can provide dependable reference material for assay development and biomarker research. Validation may involve repeat sequencing, confirmation through PCR, digital PCR, Sanger sequencing or another appropriate orthogonal method. The required validation level should be defined before procurement, as an interpreted clinical report and a research-grade variant call may provide different degrees of evidence. Researchers should review the assay’s analytical sensitivity, sequencing depth, coverage and variant allele frequency.
Â
Where possible, matched normal DNA can help confirm that the alteration is somatic rather than germline. Pathology quality control should confirm diagnosis, tumour percentage, necrosis and sufficient residual tissue for the proposed experiments. Researchers may also request H&E images, extracted DNA, unstained sections or tissue curls. When supplied with transparent molecular documentation and appropriate ethical permissions, these blocks can support positive-control development, comparative testing and validation of mutation-detection methods.
Somatic Mutation-Profiled FFPE Samples for Biomarker Studies
Somatic mutation-profiled FFPE samples can help researchers investigate whether particular genomic alterations are associated with protein expression, tissue morphology, immune features or clinical outcomes. Mutation-positive and appropriately defined mutation-negative samples may be compared using IHC, multiplex imaging, FISH, PCR, transcriptomics or spatial profiling. Existing genomic results allow researchers to enrich the cohort for relevant alterations and reduce the need for extensive initial screening.
Negative controls should be selected carefully: the original assay must have adequately covered the gene, exon and alteration type being investigated. Other variables—including tumour type, stage, treatment exposure, fixation and tumour content—should be balanced to reduce bias. Where outcome data are involved, response criteria and follow-up intervals should be clearly defined. Pathologist review can confirm representative tumour and guide macrodissection or region selection. Well-curated somatic mutation-profiled FFPE samples can support exploratory biomarker identification, assay optimisation and subsequent validation studies.
Order Molecularly Profiled FFPE Blocks for Precision Oncology
Molecularly profiled FFPE blocks can be ordered for precision-oncology research using detailed pathological, genomic and clinical criteria. Researchers may request blocks containing actionable mutations, resistance-associated variants, gene amplifications, deletions, fusions or selected genomic signatures. The specification should identify the tumour indication, histological subtype, stage, specimen site, treatment setting, minimum tumour percentage and required tissue quantity. Acceptable profiling methods—such as targeted NGS, comprehensive genomic profiling, WES or orthogonal testing—should also be defined.
A preliminary specimen manifest can be reviewed before procurement to confirm diagnosis, molecular eligibility and available annotations. Supporting documentation may include H&E images, pathology summaries, de-identified genomic reports and test-quality information. Additional services may include slide preparation, tissue curls, macrodissection, nucleic-acid extraction or mutation confirmation. A customised ordering process helps researchers build focused precision-oncology cohorts while maintaining traceability, ethical compliance and consistent quality-control standards.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.